Condition · Immune, Gut & Inflammation
Immune Function / Inflammation
01
Evidence-ranked peptides
| Peptide | Use | Evidence |
|---|---|---|
| Vasoactive Intestinal Peptide A 28-amino-acid endogenous neuropeptide that activates VPAC receptors and regulates vascular, pulmonary, gastrointestinal, neural and immune functions. | Immune Function / Inflammation weak | Human3/5 Animal0/5 Safety2/5 3 verified refs |
| Vilon A synthetic dipeptide promoted for immune, thymic and healthy-ageing effects, supported mainly by preclinical and regional literature. | Immune Function / Inflammation insufficient | Human0/5 Animal2/5 Safety0/5 1 verified ref |
| LL-37 LL-37 is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| KPV KPV is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Livagen Livagen is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Thyreogen Thyreogen is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Endoluten Endoluten is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Chonluten Chonluten is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Thymosin Alpha 1 Thymosin Alpha 1 is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials. | Immune Function / Inflammation moderate | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Bronchogen Bronchogen is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Cardiogen Cardiogen is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Cristagen Cristagen is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Thymulin Thymulin is an endogenous signalling peptide with established or emerging physiological relevance. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Edp Peptide Edp Peptide is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Ke Peptide Ke Peptide is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Cartalax Cartalax is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Ovagen Ovagen is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Thymopentin Thymopentin is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials. | Immune Function / Inflammation moderate | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Thymogen Thymogen is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Livatex Livatex is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Renisamine Peptide Renisamine Peptide is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Sigumir Sigumir is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse. | Immune Function / Inflammation insufficient | Human0/5 Animal0/5 Safety0/5 0 verified refs |
02
Current standard management
conventional medicineEvidence-based non-peptide options — including exercise, sleep, nutrition, physiotherapy and licensed medical treatments — often have stronger human evidence than research peptides.
Medical disclaimer —Standard-of-care information is educational only. Do not change or start treatment based on Atlas content. Always consult a qualified clinician for personal medical decisions.
04
Linked mechanisms
biological pathways discussed for this condition- Immune modulationneeds review
- Inflammation modulationneeds review
- Antimicrobial activityneeds review
- Cytokine signallingneeds review
- Barrier immunityneeds review
- Inflammation modulationlimited
- Gut barrier integritylimited
- Antimicrobial activitylimited
- Immune modulationlimited
- Wound repairlimited
- VPAC receptor signallingmoderate
- Short peptide gene-expression modulationlimited
03
Community observations
No approved community reports for this condition yet. Submit one.
Clinician discussion
Questions you can ask a qualified clinician
- What are the established evidence-based options for this condition?
- What monitoring is appropriate before considering any experimental intervention?
- What long-term safety data exists for peptide-based approaches?
- Are there licensed medicines relevant to my situation?
↳
Explore further
from the knowledge graphPeptides that touch this